retatrutide triple hormone receptor agonist metabolic obesity Mazdutide vs retatrutide: dual meets agonist in the next-gen weight loss showdown Retatrutide Obesity Treatment Shows Promising

The results that d-allulose moderately increased insulin release only at 15 min prompted us to explore possible additional mechanisms for the glycemic action of d-allulose

If you hit a plateau on three times weekly dosing, returning to daily dosing is a reasonable first step before escalating the dose

Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis

Retatrutide is a protein-based molecule that degrades under improper conditions

Resolved with hydration and temporary medication discontinuation

Faster titration is possible on paper but usually produces enough nausea that patients stop